88 Bibliografia [1] Thomas ED, Clift RA, Hersman J, et al. Marrow transplantation for acute nonlymphoblastic leuke- mic in first remission using fractionated or single- dose irradiation. Int J Radiat Oncol Biol Phys. 1982;8:817–21 [2] Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867–71 [3] Giebel S, Miszczyk L, Slosarek K, et al. Extreme het- erogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2014;120:2760–5 [4] Nagler A, Rocha V, Labopin M, et al. Allogeneic hema- topoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total- body irradiation plus Cy as conditioning regimen—a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:3549–56 [5] Cahu X, Labopin M, Giebel S, et al. Impact of condition- ing with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplan- tation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016;51:351–7 [6] Bacigalupo A, Ballen K, Rizzo D, et al. Defining the inten- sity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33 [7] Tutschka PJ, Copelan EA, Klein JP. Bone marrow trans- plantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382–8 [8] Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allo- geneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439–43 [9] Hassan M. The role of busulfan in bone marrow transplan- tation. Med Oncol. 1999;16:166–76 [10] Nagler A, Labopin M, Berger R, et al. Allogeneic hema- topoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syn- drome. Bone Marrow Transplant. 2014;49:628–33 [11] Vey N, De Prijck B, Faucher C, et al. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refrac- tory or relapsed hematological malignancies. Bone Marrow Transplant. 1996;18:495–9 [12] Czyz A, Labopin M, Giebel S, et al. Cyclophosphamide versus etoposide in combination with total body irra- diation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergo- ing allogeneic stem cell transplant: on behalf of the ALWP of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93:778–85 [13] Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525–36 [14] Eder S, Canaani J, Beohou E, et al. Thiotepa-based condi- tioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplan- tation for acute lymphoblastic leukemia: a matched- pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92:997–1003 [15] Chevallier P, Labopin M, Buchholz S, et al. Clofarabine- containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol. 2012;89:214–9 [16] Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alter- native to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malig- nant and nonmalignant hematologic diseases. Blood. 1998;91:756–63 [17] McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–400 [18] Giralt S, Estey E, Albitar M, et al. Engraftment of allo- geneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft- versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–6 [19] Kharfan-Dabaja MA, Labopin M, Bazarbachi A, et al. Comparing i.v. BU dose intensity between two regi- mens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2014;49:1170–5 [20] Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative con- ditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304–12 [21] Danylesko I, Shimoni A, Nagler A. Treosulfan-based con- ditioning before hematopoietic SCT: more than a BU look-alike. Bone Marrow Transplant. 2012;47:5–14 [22] Nagler A, Labopin M, Beelen D, et al. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2017;123:2671–9 [23] Shimoni A, Labopin M, Savani B, et al. Long-term sur- vival and late events after allogeneic stem cell trans- plantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol. 2016;9:118 [24] Poiré X, Labopin M, Cornelissen JJ, et al. Outcome of conditioning intensity in acute myeloid leuke- mia with monosomal karyotype in patients over 45 year-old: a study from the acute leukemia working party (ALWP) of the European Group of Blood and Marrow Transplantation (EBMT). Am J Hematol. 2015;90:719– 24 [25] Shimoni A, Labopin M, Savani B, et al. Intravenous busulfan compared with treosulfan-based condition- ing for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018;24:751–7 [26] Saraceni F, Labopin M, Hamladji RM, et al. Thiotepa- busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget. 2017;9:3379–93 [27] Malard F, Labopin M, Stuhler G, et al. Sequential inten- sified conditioning regimen allogeneic hematopoi- etic stem cell transplantation in adult patients with intermediate- or high-risk acute myeloid leukemia in complete remission: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:278–84 1. Aspetti Generali
RkJQdWJsaXNoZXIy ODUzNzk5